Cranford, NJ - May 19, 2023 -- WBB Research Institute (WBBRI) hosted a Demi-Colton Virtual Salon on the need for a global response to Candida auris and other deadly pathogens. Antimicrobial resistant C. auris is becoming a major public health threat and is found in over 30 countries causing outbreaks in hospitals, nursing homes, and other healthcare settings. It or another emerging antimicrobial resistant pathogen will likely be the cause of the next global pandemic. Scynexis (NASDAQ: SCYX) and T2 Biosystems (NASDAQ: TTOO) were two of the public companies that participated in the webinar, which highlighted the need for increased collaboration between academia, government agencies and the private sector to accelerate the development and use of rapid blood diagnostics and novel therapeutics.
Featured in this program were clinicians, government experts, and public sector leaders discussing ways to combat life-threatening pathogens to include C. auris. The webinar focused on how these pathogens became a critical threat and the real-time steps to address these threats, including rapid diagnostics and novel therapeutics. Participating in the webinar were:
- Michael Kurilla, MD, PhD, Director of the National Center for Advancing Translational Sciences at the National Institutes of Health;
- Prabhavathi Fernandes, PhD, Chair of the National Preparedness & Response Science Board, a federal advisory committee within the Department of Health and Human Services;
- Robin Robinson, PhD, Former Director of The Biomedical Advanced Research and Development Authority (BARDA);
- John Sperzel, President & CEO of T2 Biosystems;
- David Angulo, MD, President & CEO of Scynexis; and
- Thomas Walsh, MD, Founding Director of the Center for Innovative Therapeutics and Diagnostics.
"We must muster a response similar to the Covid-19 collaboration between clinicians, academia, government and the private sector in the fight against C. auris and other emerging pathogens," explained Steve Brozak, DMH, Managing Partner and President of WBB Securities, which founded the WBBRI. "The WBB Research Institute is committed to advancing the use of innovative diagnostics and therapeutics in the fight against the threat of emerging pathogens.”
The WBB Research Institute is a research organization, founded by WBB Securities. The Institute focuses on emerging critical issues in healthcare that threaten to have profound impact. WBB Securities is a leading Investment Management, Investment Banking, and Equity Research firm focused on the life sciences. WBB Securities is registered with the SEC as a broker-dealer, a FINRA member firm, and a Registered Investment Advisor with a proprietary trading desk. The firm is comprised of a nationwide team of respected senior investment and research professionals serving institutional and high-net-worth clients.
Demy-Colton
Demy Colton is a leader in biotech and life science events, with over 20 years of experience connecting leaders of innovative biotech companies with key stakeholders, investors, and advisors, we create ideal environments to examine and address opportunities and challenges in today’s biotech industry.
